There is a large unmet need for effective and safe anti-obesity treatments. Glycemicon aims to fill this gap by identifying natural occurring compounds that activate brown adipose tissue. Targeting the brown fat tissue is a novel approach, which addresses the key problem of obesity: the imbalance between energy intake and expenditure. Brown fat cells break down stored energy by dissipating energy in the form of heat, which leads to an increased energy expenditure of the body.
Collaborations with academic groups such as the ETH will provide new product opportunities, which may also include product candidates that can be out-licensed or partnered at an early stage.